For instance, bortezomib, a drug that interferes with protein breakdown, can suppress tumor survival signals, while cytokine blockers such as canakinumab (which targets IL-1β) and tocilizumab (which targets IL-6) have shown the potential to lower cancer risk and improve response to therapy [109,110,111,112,113,114,115,116]. This evidence concerns the gene IL1B and cancer.